Global prescriptions for GLP‑1 medications such as semaglutide and tirzepatide are on pace to exceed $50 billion annually, yet up to 30 percent of patients miss or delay at least one weekly dose in the first three months, eroding clinical outcomes and driving costly drug waste. GLP‑1 Tracker (“GLP-1 Tracker”) enters the market today with a single goal: convert those high‑stakes injections into a se
Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=338825
